loader2
Partner With Us NRI

RPG Life Sciences Ltd share Price Today

Company details

1,492.10
1,530.00
748.60
1,740.00
6M Return 5.10%
1Y Return 93.98%
Mkt Cap.(Cr) 2,505.00
Volume 14,996
Div Yield 1.06%
OI
-
OI Chg %
-
Volume 14,996

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company RPG Life Sciences announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue Growth: RPG Life Sciences reported a YoY revenue increase for the Q4FY24, with revenue from operations going up from Rs 118.49 crore to Rs 126.99 crore, marking a 7% growth.
  • Profit Before Tax (PBT): The company experienced a significant jump in PBT of 28% YoY for Q4FY24, climbing from Rs 13.81 crore to Rs 17.74 crore. 
  • EBITDA Margin Expansion: There has been a notable improvement in EBITDA margins, from 15% to 17.6% YoY for Q4.

FY24 Financial Highlights:

  • Revenue Growth: The full-year performance was also strong, with revenues increasing by 14% to Rs 582.05 crore for FY24, up from the previous year's Rs 512.81 crore.
  • Profit Before Tax (PBT): For the full fiscal year, PBT surged by 29%, with figures reaching Rs 117.84 crore compared to the earlier Rs 91.68 crore. 
  • EBITDA Margin Expansion: A YoY rise for the full year from 21.0% to 23.3%.

Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q4FY24, the overall performance of the Company continued to be strong. Revenue and PBT grew by 7% and 28% respectively YoY. The EBITDA margin retained its 5-yearlong upward trajectory growing from 21.0% to 23.3% YoY. The Company continues to remain debt-free.

We are well on course in executing all the tenets of our distinctive and smart transformation agenda to achieve our strategic goal of consistent, healthy, and profitable growth. Our top priority, Domestic Formulations, the biggest contributor to the Company’s business, recorded robust growth in both value and volume - significantly and consistently ahead of the marketbased on its 5 pillar-growth strategy. The comprehensive smart life cycle management program is shaping some of our ‘textbook’ legacy brands into mega brands and our niche specialty portfolio into mega portfolio. New launches in specialty and chronic therapies are helping us shape our Specialty business. We are now working on replicating our smart and successful Rheumatology portfolio entry strategy to enter other specialties like Gastro and Derma to emerge as future growth drivers of Domestic Formulations business. Our MABs portfolio continues to post robust performance. Salesforce productivity continues to register healthy upward momentum, assisted by smart deployment of digital.

We are now shaping our International Formulations and API business basis their own 5 pillars, the key being plants modernization cum capacity expansion by infusion of capex and building a smart product pipeline to become strong futuregrowth drivers. The International Formulations business has been registering healthy double-digit growth. Modernization of our API Plant and building product pipeline, both currently underway, will make API also our third engine of growth.

Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain 5-year uninterrupted YoY margin expansion trajectory for the past 5 consecutive years.” 


     

Result PDF

View Other Company Results

RPG Life Sciences Ltd shares SWOT Analysis

Strengths (13)

  • MACD Crossover Above Signal Line
  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth

Weakness (0)

Data not found

Opportunity (1)

  • Highest Recovery from 52 Week Low

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 1,525.6
R2 1,547.7
R3 1,570.7
Pivot

1,502.67

S1 1,480.6
S2 1,457.6
S3 1,435.5
EMA SMA
1,493.4
1,505.9
1,483.9
1,378.9
1,498.4
1,504.7
1,514.3
1,410.1
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
XTX MARKETS LLP Bulk Purchase 2021-09-21 730.53 135708 NSE
XTX MARKETS LLP Bulk Sell 2021-09-21 731.47 136929 NSE
XTX MARKETS LLP Bulk Purchase 2021-09-03 596 89624 NSE
Name Category Shares
Nucleus Life Trust (Mr. Harsh Vardhan Goenka is a Trustee) PROMOTER 53.8%
Ektara Enterprises LLP PROMOTER 15.57%
STEL Holdings Limited PROMOTER 3.18%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

RPG Life Sciences Ltd Stocks COMPARISON

Financials( in Cr) RPG Life Sciences Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 1,514.60 1,531.40 1,399.05 1,051.40 3,910.75
% Change 4.19 0.26 -0.54 5.45 0.47
Mcap Cr 2,505.00 367,434.16 112,954.68 105,795.44 103,818.29
Revenue TTM Cr 512.81 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr 67.64 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 28.35 39.15 26.62 28.83 75.36
1 Year Return 93.98 60.69 51.61 103.07 19.36
ROCE 32.15 16.79 14.76 16.25 19.30
ROE 24.01 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 307.60 Cr FV: 8.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 45,096.27 -32,431.93
LAST 3M 105,135.14 -41,239.38
LAST 6M 172,248.08 48,806.90
LAST 12M 264,707.07 127,969.33

RPG Life Sciences Ltd Information

Stock PE (TTM)
28.35
Promoter Holding
72.81%
Book Value
226.6466
ROCE
32.15%
ROE
24.01%
Description
  • RPG Life Sciences, formerly Searle India Ltd, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The company is having research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. They are having TGA (Aus) and MHRA (UK) approved facilities at Thane in Maharashtra and Ankleshwar in Gujarat. RPG Life Sciences Ltd was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Ltd. During the year 2007-08, as per the scheme of arrangement, the company acquired the pharmaceuticals business of Brabourne Enterprises Ltd along with all assets and liabilities pertaining to that business with effect from April 2, 2007 (the appointed date). In February 13, 2008, the name of the company was subsequently changed to RPG Life Sciences Ltd. During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments. The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology. New products launched were Demator, Sizomax, Mela, Exinia and Mofetyl S during the year 2009-10. The Company strengthened its product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. It launched a new immunosuppressant product, Sirolimus in 2010. New divisions were launched in highly growing chronic segments namely Cardiology and Diabetic (IMPULSE), NeurologyPsychiatry (EMPATHY) and Oncology (Neo-life). A new division ESSENTIA was also launched to cater to the Hospital sales segment in 2010-11. New products launched were Seretane 2 DT, Rabee 20, Pedimec, Minilactone, Alfalog, Demator, Naprosyn Gel, Lamotrigine dispersible tablets. The Company sold its Biotech Unit located at Ankleshwar to M/s. Intas Pharmaceuticals Limited as a going concern in 2016-17. It acquired 7 brands from Sun Pharmaceuticals Limited, set up two new divisions viz. `Urolife` catering to the urology therapy and `Glodiance` division catering to the Cosmetic Derma therapy in 2016-17. In 2017-18, the Company launched brands Darbepoetin (Darba) and Rituximab (XMAB), in the post-transplant care space. Both the brands displayed robust performances in the first year of launch with Darba at third slot among competing Darbepoetin brands. Among the existing products, Immunotac and Arpimune range showed strong growth. In the Africa region, the Company expanded its business with first commercial supply in FY`18. It retained leadership position in Mauritius, through anti-diabetic range while in Egypt, immunosuppressant range remained the best alternative to the innovator brands in the post organ transplant care space. During 2019, the Company focused on launching new products and driving active promotion in the immunosuppressant range of products and strengthened the oncology portfolio basket by introducing two new monoclonal antibodies. It launched a new product, T-JAKi (JAK Inhibitor) in the immunosuppressant range of products in Rheumatology and Gastroenterology in FY21. As a part of Life Cycle Management strategy of legacy products, Romilast BL and Aldactone T new line extensions were launched. Azoran 75 mg new line extension was launched in 2021. Naprosyn and Aldactone-F was launched in FY`22.

Registered Address

RPG House, 463 Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Tel : 91-022-24981650
Email : info:rpglifesciences.com
Website : http://www.rpglifesciences.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 8
Market Lot Equity Shares : 1
BSE Code : 532983
NSE Code : RPGLIFE
Book Closure Date (Month) :
BSE Group : B
ISIN : INE105J01010

FAQ’s on RPG Life Sciences Ltd Shares

You can buy RPG Life Sciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy RPG Life Sciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 17, 2024 03:42 PM the closing price of RPG Life Sciences Ltd was Rs.1,514.60.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 17, 2024 03:42 PM, the market cap of RPG Life Sciences Ltd stood at Rs. 2,505.00.

The latest PE ratio of RPG Life Sciences Ltd as of May 17, 2024 03:42 PM is 28.35

The latest PB ratio of RPG Life Sciences Ltd as of May 17, 2024 03:42 PM is 0.15

The 52-week high of RPG Life Sciences Ltd share price is Rs. 1,740.00 while the 52-week low is Rs. 748.60

Download App

Download Our App

Play Store App Store
market app